A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Margaret Hux; Denise Zou; Esprit Ma; Peter Sajosi; Andreas Engstrom; Ross Selby; Eugene Benson; Andrew Briggs; Vijayveer Bonthapally

doi:10.36469/9820

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

JHEOR

Articles
For Authors
Editorial Board
About
Issues
Blog
Journal Policies
For Reviewers

search
X (formerly Twitter) (opens in a new tab)
Bluesky (opens in a new tab)
LinkedIn (opens in a new tab)
RSS feed (opens a modal with a link to feed)

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:53949/feed

ISSN 2327-2236

Oncology

Vol. 4, Issue 2, 2017

October 26, 2016 EDT

A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Margaret Hux, Denise Zou, Esprit Ma, Peter Sajosi, Andreas Engstrom, Ross Selby, Eugene Benson, Andrew Briggs, Vijayveer Bonthapally,

incremental cost-effectiveness ratioquality-adjusted life yearchemotherapysystemic anaplastic large cell lymphomabrentuximab vedotincost-effectiveness

ccby-4.0

• https://doi.org/10.36469/9820

JHEOR

Hux M, Zou D, Ma E, et al. A Cost-effectiveness Analysis of Brentuximab Vedotin in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. JHEOR. 2016;4(2):188-203. doi:10.36469/9820

View more stats